Physician profile
John J White
NPI 1699878108
$1,766.78
in general payments reported to CMS, 2019-2025
26 companies · $215 in 2025
The $215 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $410 · 2020: $305 · 2021: $154 · 2022: $289 · 2023: $181 · 2024: $213 · 2025: $215.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $609.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $609.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $570.06 | 2019-2023 | Farxiga |
| Novartis Pharmaceuticals Corporation | $131.81 | 2024-2025 | |
| Pfizer INC. | $120.61 | 2021-2024 | |
| Alexion Pharmaceuticals, INC. | $112.00 | 2019 | |
| Amgen INC. | $104.63 | 2019-2024 | Repatha, Otezla |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $85.20 | 2023-2025 | Xifaxan, Trulance |
| La Jolla Pharmaceutical Company | $76.64 | 2022 | |
| Vifor Pharma, INC. | $62.20 | 2019-2021 | |
| Idorsia Pharmaceuticals US INC | $51.69 | 2023 | Quviviq |
| Glaxosmithkline, LLC. | $51.38 | 2023-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbvie INC. | $44.07 | 2022-2023 | Vraylar |
| Akebia Therapeutics INC | $40.31 | 2019-2020 | |
| Exact Sciences Corporation | $36.65 | 2025 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $36.61 | 2022-2023 | |
| Fresenius USA Marketing, INC. | $34.70 | 2020-2024 | Velphoro |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $31.08 | 2021-2022 | |
| Vital Connect, INC | $26.50 | 2025 | Vitalpatch Rtm |
| Renalytix Ai, INC. | $20.12 | 2022 | |
| Axonics, INC. | $18.40 | 2022 | |
| Daiichi Sankyo INC. | $18.36 | 2019 | |
| Opko Pharmaceuticals, LLC | $17.63 | 2020 | |
| Merck Sharp & Dohme LLC | $17.24 | 2024 | Capvaxive, Gardasil, Gardasil 9 |
| Kowa Pharmaceuticals America, INC. | $16.85 | 2022 | |
| Inspire Medical Systems, INC. | $16.01 | 2025 | Inspire |
| Esperion Therapeutics, INC. | $14.38 | 2025 | Nexletol |
| Mallinckrodt Enterprises LLC | $11.65 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John White listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.